Autoimmune Lymphoproliferative Syndrome (ALPS): Evaluation and Management
For patients presenting with chronic unexplained lymphadenopathy and splenomegaly, particularly in childhood, ALPS should be suspected and diagnosed using the revised NIH criteria, which require specific laboratory markers including elevated double-negative T cells (DNTs) and biomarkers, followed by genetic testing for FAS pathway mutations 1.
Diagnostic Approach
Required Clinical Features
The diagnosis of ALPS requires a systematic evaluation based on the 2009 NIH revised criteria 1:
Primary Required Criteria:
- Chronic (>6 months) nonmalignant, non-infectious lymphadenopathy and/or splenomegaly
- Elevated CD3+TCRαβ+CD4-CD8- (double-negative T) cells ≥1.5% of total lymphocytes or ≥2.5% of CD3+ lymphocytes 1, 2
Secondary Criteria to Support Diagnosis:
- Defective lymphocyte apoptosis in vitro (FAS-mediated apoptosis assay)
- Somatic or germline pathogenic variants in FAS, FASL, or CASP10 genes 1, 2
- Elevated biomarkers: soluble FAS ligand (sFASL) >200 pg/mL, vitamin B12 >1500 ng/L, IL-10 >20 pg/mL 1
- Immunohistochemistry showing paracortical expansion of DNTs in lymph node biopsy 3
Key Clinical Presentations to Recognize
Look specifically for:
- Childhood onset (though adult presentations increasingly recognized) 4
- Multilineage cytopenias (autoimmune hemolytic anemia, immune thrombocytopenia, autoimmune neutropenia) 2, 5
- Family history of similar lymphoproliferation or autoimmune disease 1
- Absence of infectious symptoms or constitutional B symptoms initially 1
Diagnostic Pitfalls
The differential diagnosis includes infections, other immunodeficiency disorders, primary autoimmune syndromes, and lymphoma 3. Avoid empiric corticosteroids before establishing diagnosis, as they can mask lymphoma histology 6. Approximately one-third of ALPS patients have unidentified genetic defects despite meeting clinical criteria 1.
Management Strategy
First-Line Chronic Treatment
Sirolimus (rapamycin) is the best-studied and most effective corticosteroid-sparing therapy for ALPS and should be considered first-line for patients requiring chronic treatment 7, 5, 8.
Treatment Algorithm by Severity
For Mild Disease (asymptomatic lymphoproliferation):
- Observation with regular monitoring for cytopenias and lymphoma development 5
For Moderate Disease (symptomatic cytopenias or significant organomegaly):
- Sirolimus as first-line steroid-sparing agent 7, 8
- Mycophenolate mofetil as alternative immunosuppressive option 2, 8
- Short-course corticosteroids for acute autoimmune flares 5
For Severe Refractory Disease:
- Rituximab for refractory autoimmune cytopenias 2
- Intravenous immunoglobulin (IVIG) for acute management 2
- Splenectomy may be considered for severe sequestration, though increases infection risk 5
For Life-Threatening Disease:
- Hematopoietic stem cell transplantation is the only curative therapy but reserved for severe cases due to transplant-related complications 2
Critical Long-Term Monitoring
Patients with FAS mutations affecting the intracellular domain have significantly increased lifetime risk of B-cell lymphoma 5. This requires:
- Regular surveillance for lymphoma development (clinical examination, imaging as indicated)
- Monitoring for progression of cytopenias
- Assessment for new autoimmune manifestations beyond hematologic involvement
Genetic Counseling Considerations
Most patients harbor heterozygous germline FAS mutations inherited in autosomal dominant fashion, though somatic FAS mutations are the second most common cause [1, @12@]. Family screening should be offered given the hereditary nature in most cases.
The absence of standardized treatment protocols reflects the rarity of ALPS (>2200 reported patients worldwide) 2, but the evidence strongly supports sirolimus as the preferred long-term management strategy based on efficacy and steroid-sparing properties 7, 8.